Nanoparticles boost radiation to fight advanced cancer in new trial

NCT ID NCT05039632

First seen Jun 24, 2026 · Last updated Jul 31, 2026 · Updated 5 times

Summary

This phase I/II trial tests whether injecting NBTXR3 nanoparticles into tumors can make radiation more effective, combined with immunotherapy (anti-PD-1/PD-L1), for patients with advanced solid cancers that have spread to the lung or liver. The study aims to see if this approach can shrink tumors and control the disease. About 40 participants will receive the treatment, and researchers will monitor side effects and tumor response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
NBTXR3 nanoparticles (hafnium oxide) injected into tumors, plus radiation therapy and anti-PD-1/PD-L1 immunotherapy (e.g., nivolumab)
What this could lead to
If successful, this could offer a new way to control advanced cancers that have spread to the lung or liver, potentially shrinking tumors and extending life.
What could go wrong
This is an early phase I/II trial with only 40 participants, so results are preliminary. The combination may cause serious side effects, and not all patients may respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • M D Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.